Local Production of Pharmaceuticals : Industrial Policy and Access to Medicines, An Overview of Key Concepts, Issues and Opportunities for Future Research

Local production of pharmaceuticals in developing countries may be seen as helping to stimulate industrial policy and/or as stimulating pharmaceutical access to needed medicines. However, if a developing country with manufacturing facilities is able to finish off bulk active ingredients sourced from developed or other countries at high costs, such manufacture may have no impact whatever on patient access to needed medicines. There has been some critical thinking in the past regarding whether or not small developing countries should make their own pharmaceuticals, but no recent comprehensive summary of the issues and policy options. This paper summarizes the issues surrounding local production from a policy and public health viewpoint. It provides four brief country-level case studies, and reviews the evidence supporting the industrial policy assumptions underlying the goal of local production. In brief, in many parts of the world, producing medicines domestically makes little economic sense. If many countries begin local production, the result may be less access to medicines, since economies of scale may be lost if there are production facilities in many countries. The document concludes by providing a research agenda specifically designed to test assumptions about local production of pharmaceuticals.

Saved in:
Bibliographic Details
Main Authors: Kaplan, Warren, Laing, Richard
Language:English
en_US
Published: World Bank, Washington, DC 2005-01
Subjects:ADVERTISING, ANTIBIOTICS, ANTIHISTAMINES, BENCHMARKING, CHEMISTS, COMMUNICABLE DISEASES, COMPETITIVE ADVANTAGE, COMPETITIVENESS, CRIME, DEPRESSANTS, DEVELOPED COUNTRIES, DIABETES, DRUG MANUFACTURING, DRUG POLICIES, ECONOMIC DEVELOPMENT, ECONOMIC WELFARE, ECONOMIC, TRADE, ECONOMICS, ECONOMIES OF SCALE, EFFECTIVE USE, EMPLOYMENT, EQUIPMENT, ESSENTIAL DRUGS, EXPORTS, FINANCIAL SECTOR, FUTURE RESEARCH, GENERIC PRODUCTS, GMP, HEALTH, HEALTH CARE, HEALTH POLICY, HEALTH SERVICES, HIV/AIDS, HOLIDAYS, HORMONES, HOSPITALS, HUMAN DEVELOPMENT, IMPORTS, INCOME, INDUSTRIALIZATION, INFECTIOUS DISEASES, INFLATION, INSULIN, LOCAL PHARMACEUTICAL PRODUCTION, LOCAL PRODUCTION, MALARIA, MEDICINE, MEDICINES, MIDDLE INCOME COUNTRIES, NATIONAL DRUG POLICY, NUTRITION, PATENTS, PATIENTS, PHARMACEUTICAL DOSAGE FORMS, PHARMACEUTICAL INDUSTRY, PHARMACEUTICAL MANUFACTURE, PHARMACEUTICAL MANUFACTURERS, PHARMACEUTICAL PRODUCTS, PHARMACEUTICALS, PHARMACY, POLICY, POLITICAL ECONOMY, PRIVATE SECTOR, PRODUCERS, PROPERTY RIGHTS, PUBLIC HEALTH, PUBLIC SECTOR, PURCHASING POWER, QUALITY CONTROL, REGULATORY SYSTEMS, RESEARCH AGENDA, SOLVENTS, STIMULANTS, SUPPLY, DEMAND, TAX RATES, TRADE BALANCE, TRADITIONAL MEDICINES, VACCINES, VALUE ADDED, VITAMINS, WORKERS,
Online Access:http://documents.worldbank.org/curated/en/2005/01/5733898/local-production-pharmaceuticals-industrial-policy-access-medicines-overview-key-concepts-issues-opportunities-future-research
https://hdl.handle.net/10986/13723
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Local production of pharmaceuticals in developing countries may be seen as helping to stimulate industrial policy and/or as stimulating pharmaceutical access to needed medicines. However, if a developing country with manufacturing facilities is able to finish off bulk active ingredients sourced from developed or other countries at high costs, such manufacture may have no impact whatever on patient access to needed medicines. There has been some critical thinking in the past regarding whether or not small developing countries should make their own pharmaceuticals, but no recent comprehensive summary of the issues and policy options. This paper summarizes the issues surrounding local production from a policy and public health viewpoint. It provides four brief country-level case studies, and reviews the evidence supporting the industrial policy assumptions underlying the goal of local production. In brief, in many parts of the world, producing medicines domestically makes little economic sense. If many countries begin local production, the result may be less access to medicines, since economies of scale may be lost if there are production facilities in many countries. The document concludes by providing a research agenda specifically designed to test assumptions about local production of pharmaceuticals.